| Sales | 2.29B |
| Cost of sales | 1.67B |
| Gross profit | 621M |
| Selling, general and administrative expenses | 181M |
| Research and development expenses | 54M |
| Asset impairments and restructuring charges (gains), net | 30M |
| Operating earnings | 356M |
| Net interest expense | 64M |
| Other charges (income), net | 3M |
| Earnings from continuing operations before income taxes | 289M |
| Provision for income taxes from continuing operations | 56M |
| Earnings from continuing operations | |
| Earnings from discontinued operations, net of tax | |
| Gain from disposal of discontinued operations, net of tax | |
| Net earnings | 232M |
| Basic earnings per share | |
| Earnings from continuing operations | |
| Earnings (loss) from discontinued operations | |
| Basic earnings per share | 1.57 |
| Diluted earnings per share | |
| Earnings from continuing operations | |
| Earnings (loss) from discontinued operations | |
| Diluted earnings per share | 1.56 |
| Net earnings | 232M |
| Change in cumulative translation adjustment | |
| Unrecognized Losses and Prior Service Credits for Benefit Plans | |
| Change in unrealized gains (losses) on derivative instruments | -7M |
| Total other comprehensive income (loss), net of tax | |
| Comprehensive income | 195M |
| Retained earnings at beginning of period | 5.52B |
| Net earnings | |
| Cash dividends declared | -69M |
| Retained earnings at end of period | 5.68B |